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Abstract
Understanding the mechanisms of cell function and drug action is a major endeavor in the pharmaceutical industry. Drug
effects are governed by the intrinsic properties of the drug (i.e., selectivity and potency) and the specific signaling
transduction network of the host (i.e., normal vs. diseased cells). Here, we describe an unbiased, phosphoproteomic-based
approach to identify drug effects by monitoring drug-induced topology alterations. With our proposed method, drug
effects are investigated under diverse stimulations of the signaling network. Starting with a generic pathway made of logical
gates, we build a cell-type specific map by constraining it to fit 13 key phopshoprotein signals under 55 experimental
conditions. Fitting is performed via an Integer Linear Program (ILP) formulation and solution by standard ILP solvers; a
procedure that drastically outperforms previous fitting schemes. Then, knowing the cell’s topology, we monitor the same
key phosphoprotein signals under the presence of drug and we re-optimize the specific map to reveal drug-induced
topology alterations. To prove our case, we make a topology for the hepatocytic cell-line HepG2 and we evaluate the effects
of 4 drugs: 3 selective inhibitors for the Epidermal Growth Factor Receptor (EGFR) and a non-selective drug. We confirm
effects easily predictable from the drugs’ main target (i.e., EGFR inhibitors blocks the EGFR pathway) but we also uncover
unanticipated effects due to either drug promiscuity or the cell’s specific topology. An interesting finding is that the
selective EGFR inhibitor Gefitinib inhibits signaling downstream the Interleukin-1alpha (IL1a) pathway; an effect that cannot
be extracted from binding affinity-based approaches. Our method represents an unbiased approach to identify drug effects
on small to medium size pathways which is scalable to larger topologies with any type of signaling interventions (small
molecules, RNAi, etc). The method can reveal drug effects on pathways, the cornerstone for identifying mechanisms of
drug’s efficacy.
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Introduction
Target-based drug discovery is a predominant focus of the
pharmaceutical industry. The primary objective is to selectively
target protein(s) within diseased cells in order to ameliorate an
undesired phenotype, e.g., unrestrained cell proliferation or
inflammatory cytokine release. Ideally, other pathways within
the diseased cells, as well as similar phenotypes in other cell types,
should remain unaffected by the therapeutic approach. However,
despite the plethora of new potential targets emerged from the
sequencing of the human genome, rather few have proven
effective in the clinic [1]. A major limitation is the inability to
understand the mechanisms or drug actions either due to the
complex signaling transduction networks of cells or due to the
complicated profile of drug potency and selectivity.
Finding drug’s targets is traditionally based on high-throughput
in vitro assays using recombinant enzymes or protein fragments [2].
The main goal is to characterize the drug’s biochemical activity
(binding affinities that describe potency and selectivity) and depict
them in drug-interaction maps [3]. In most cases, once the target(s)
is known, the in vivo effect on the signaling pathway is validated by
measuring the drug’s efficiency to inhibit the activity (usually
measured as phosphorylation level [4]) of the downstream protein.
However, beyond that measurement, little is know on how the rest
of the signaling network is affected. In addition, in vivo drug effects
can hardly be calculated from in vitro assays for several reasons:
most kinase inhibitors are promiscuous [5], there is discrepancy
between in vivo and in vitro binding affinities of drugs [6], and there
is an additional discrepancy between in vivo binding affinities and
in vivo inhibitor activity for the phosphorylation of downstream
signals.
To address drug effects in more physiological conditions, novel
genomic and proteomic tools have recently been developed [7]. In
the genomic arena, large-scale mRNA analysis (e.g., [8,9])
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lution (e.g., [10,11]) have been developed. Despite the holistic
advantages that genomic approaches have to offer, proteomic-
based discovery is a step closer to the function of the cell. Towards
this goal, affinity chromatography offers a viable strategy for in-vivo
target identification. This approach utilizes a solid support linked
to a bait (usually the drug) to enrich for cellular binding proteins
that are identified by mass spectrometry (MS) [12]. However, such
experiments usually require large amounts of starting protein, are
biased toward more abundant proteins, and result in several hits
due to nonspecific interactions [13,14]. In order to circumvent the
non-specific interaction problem, another bait-based strategy uses
quantitative MS with ‘‘dirty’’ inhibitors for baits to immobilize the
kinome [15,16]. While this approach significantly reduces the non-
specific interaction problem, it also limits the target-searching
space to those kinases with the highest affinity to the bait. More
recently, quantitative MS-based proteomics using SILAC tech-
nology [14] extends the search space to all targets that do not bind
covalently to the drug. However, incorporation of the SILAC’s
isotopes requires 5 population doublings and thus, excludes the
application on primary cells with limited replication capabilities.
Taken together, all techniques listed above can -in the best case
scenario- list the affinities of all targets to the drug but no
information is provided whether this binding affinity is capable of
inhibiting the transmission of the signal to the downstream protein
or how those preferential bindings can collectively affect the
signaling network of the cell.
Here, we describe a significantly different approach to identify
drug effects where drugs are evaluated by the alterations they
cause on signaling pathways. Instead of identifying binding
partners, we monitor pathway alterations by following key
phosphorylation events under several treatments with cytokines.
The workflow is presented in Figure 1. On the experimental front,
using bead-based multiplexed assays [17], we measure 13 key
phosphorylation events under more than 50 different conditions
generated by the combinatorial treatment of stimuli and selective
inhibitors. Based on the signaling response and an a-priori set of
possible reactions (i.e. generic pathway), we create a cell-type
specific pathway using an efficient optimization formulation
known as Integer Linear Programming (ILP). This approach
Author Summary
Cells are complex functional units. Signal transduction
refers to the underlying mechanism that regulates cell
function, and it is usually depicted on signaling pathways
maps. Each cell type has distinct signaling transduction
mechanisms, and several diseases arise from alterations on
the signaling pathways. Small-molecule inhibitors have
emerged as novel pharmaceutical interventions that aim
to block certain pathways in an effort to reverse the
abnormal phenotype of the diseased cells. Despite that
compounds have been well designed to hit certain
molecules (i.e., targets), little is known on how they act
on an ‘‘operative’’ signaling network. Here, we combine
novel high throughput protein-signaling measurements
and sophisticated computational techniques to evaluate
drug effects on cells. Our approach comprises of two steps:
build pathways that simulate cell function and identify
drug-induced alterations of those pathways. We employed
our approach to evaluate the effects of 4 drugs on a cancer
hepatocytic cell type. We were able to confirm the main
target of the drugs but also uncover unknown off-target
effects. By understanding the drug effects in normal and
diseased cells we can provide important information for
the analysis of clinical outcomes in order to improve drug
efficacy and safety.
Figure 1. Experimental and computational workflow to assess drug effects. (A) A Boolean generic map is assempled from pathway
databases and includes stimuli (green squares), key measured phosphoproteins (brown circles), and the neighboring proteins (yellow circles). (B) Cells
are treated with a combination of cytokines and selective inhibitors (red circles) of known effects and an ILP formulation is used to fit the data to the
Boolean pathway. (C) A cell-type specific pathway is constructed. (D) Cells are treated with a combination of cytokines and drugs –their effects are
assumed unknown- and ILP is used for the second time to fit the drug-induced phosphorylation data. (E) Alterations of the the cell-type specific
topology reveals drug effects (red arrows).
doi:10.1371/journal.pcbi.1000591.g001
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The ILP is solved using standard commercial software packages to
guaranteed global optimality (within a user-defined, numerically
small tolerance). To evaluate drug effects, we subject the cells with
the same stimuli in the presence of drugs and we tract the
alterations of the same key phosphorylation events. Then, we
reapply the ILP formulation without a-priori assumption of the
drug target, and we monitor the changes in the pathway topology
with and without drug presence. To demonstrate our approach,
we construct a generic map and optimize it to fit the
phosphoproteomic data of the transformed hepatocytic cell lines
HepG2. Then, we identify the effects of four drugs: the dual
EGFR/ErbB-2 inhibitor Lapatinib [19], two potent EGFR kinase
inhibitors Erlotinib [20] and Gefitinib [21], and the ‘‘dirty’’ Raf
kinase inhibitor Sorafenib [22]. When our method is applied on
those 4 drugs we find their main target effect and we also uncover
several unknown but equally active off-target effects. In the case of
Gefitinib, we find a surprising inhibition of cJUN in the IL1a
pathway.
In contrast to previously developed techniques, our method is
based on the actual effect on phosphorylation events carefully
spread into the signaling network. Theoretically, it can be applied
on any type of intracellular perturbations such as ATP-based and
allosteric kinase inhibitors, RNAi, shRNA etc. On the computa-
tional front, our ILP-based approach performs faster and more
efficient than current algorithms for pathway optimization [18]
and can identify the main drug effects as well as unknown off-
target effects in areas of pathways constrained between the
activated receptors and the measured phosphorylated proteins.
Our fast and unbiased characterization of modes of drug actions
can shed a light into the potential mechanisms drug’s efficacy and
toxicity.
Results
Construction of phosphoproteomic datasets
High-throughput bead-based ELISA-type experiments using
xMAP technology (Luminex, Texas, USA) are performed as
briefly described in the Materials and Methods section and in [17].
We create two datasets: one for the construction of cell-type
specific topology and another for the identification of the
mechanisms of drug actions. To do that, HepG2s are stimulated
in 10 different ways with combinatorial treatments with a diverse
set of 5 ligands (TNFa, IL1a, HGF, INS, TGFa, and no stimuli)
and either 4 highly selective inhibitors (PI3K, MEK, p38, cMET,
and no inhibitor) or 4 commercial drugs (EGFR inhibitors
Lapatinib, Erlotinib and Gefitinib, and the ‘‘dirty’’ inhibitor
Sorafenib) (Figure 1b and 1d). For the purpose of this paper, we
refer to ‘‘inhibitors’’ as the compounds for which we know the
target and we use them in a concentration capable to block ,95%
of the downstream protein. Conversely, we refer to ‘‘drugs’’ as the
compounds for which we assume no a-priori knowledge of their
target. For each combination of cytokine and drug/inhibitor we
collect cell lysates at 5 and 25 minutes. The two time points are
pooled together in 1:1 ratio and the mixed lysates are used as an
indicator of the ‘‘average early signaling response’’. For each
treatment we measure 13 protein phosphorylations that we
consider ‘‘key protein activities’’ (raw data in Figure S1). The
key phosphorylation signals (listed in Materials and Methods) are
chosen based on the availability of the reagents and quality
controls performed at the early phases of the experimental setup
[17]. The raw data (arbitrary fluorescent intensities) are normal-
ized to fit logic models as described in [18] using a non-linear
transformation that converts raw data into values between 0 and 1
where 1 corresponds to the fully activated state and 0 to no-
activation. It has to be noted that logic-transformed data depends
on what should be considered ‘‘protein activation’’ (transformed
value .0.5), a criterion that is embedded in the transformation
function and accounts for signal-to-noise limits, saturation of the
detection scheme, and eliminates biases that could have been
introduced by the variability of antibody affinities [18].
Generic pathway assembly and visualization
The generic pathway map is constructed in the neighborhood of
the 5 stimuli and the 13 measurements. The ubiquitous presence
of conflicting reports on pathway maps and alternative protein
names makes this step a highly nontrivial one. We explored several
pathway databases including STKE, Pathway Interaction Data-
base, KEGG, Pathway Commons, Ingenuity, and Pathway Studio
[23,24]. Our limited intracellular protein coverage makes
impractical the reduction of very large pathway datasets such as
those found in Pathway Commons. Here, we create the initial
topology from the union of canonical pathways found in Ingenuity
(Redwood City, California) with subsequent manual curation.
A detailed description of Boolean representation of pathways
can be found elsewhere [18,25–29]. In the present manuscript as
opposed to [18], the connectivity in our pathway (Figure 2, left
panel) is represented with OR gates and only few connections
(represented with small black circles in Figure 2) require an AND
gate. We are therefore not comparing OR vs. AND gates, but
rather assuming our pathways to be ‘causal’ graphs, and since
there are a few AND gates we refer to it as Boolean model.
Construction of cell-type specific pathway via ILP
formulation
The formulation for the optimal pathway identification is a 0–1
Integer Linear Program, i.e., an optimization problem with binary
variables and linear constraints (see Materials and Methods). The
optimizer picks values for the decision variables, such that the
logical constraints are satisfied and the objective(s) optimized. The
primary objective is to find an optimal pathway, i.e., a pathway
that best describes a set of phosphoproteomic data under a given
model (e.g. Boolean). A secondary objective is that the pathway is
as small as possible, i.e., has as few connections as possible, such
that the best-possible fit of the experiments is maintained (see
Materials and Methods). It is shown that some of the binary
variables can be relaxed to continuous, without changing the
feasible set.
The ILP is solved with the state-of-the-art commercial code
(CPLEX [30,31]) that guarantees minimal error between exper-
imental data and the Boolean topology. The goodness of fit
(percent error as described in Materials and Methods) was
decreased from 36.7% on the generic map to 8.3% on the
optimized map (Figure 2). The main source of error is the inability
of TGFa to activate the IRS1_s (serine residue of IRS1) (see the
red background on the IRS1 row at the bottom panel of Figure 2).
This is a result of the infeasibility of the generic pathway to satisfy
the activation of IRS1_s in a TGFa/IL1a-dependant but HGF/
INS-independent manner: TGFa activation of IRS1_s requires
mTOR activation via AKT which the optimization algorithm
removes to satisfy the inactivation IRS1_s by INS that shares
the same path with TGFa. This example highlights the
importance of multi-perturbations to better constrain the optimi-
zation formulation.
Figure 2 shows the optimized topology of HepG2s. Our ILP
formulation uses two subsequently-imposed objective functions to
remove reactions that do not fit the experimental data. During the
optimization of the first objective the ILP formulation (A) keeps
Phosphoproteomic Identification of Drug Effects
PLoS Computational Biology | www.ploscompbiol.org 3 December 2009 | Volume 5 | Issue 12 | e1000591Figure 2. Cell type specific topology using Integer Linear Programming. The ILP algorithm is using a subset of postulated reactions denoted
with black and gray arrows in a generic pathway to construct a HepG2 pathway map (black arrows in pathway diagram). Gray triangles show
phosphoprotein activation level upon stimuli (columns in top and bottom panels) and inhibitors (subcolumns in top and bottom panels). Red
background denotes an error between experimental and pathway-inferred responses. Generic topology can hardly represent the HepG2 signaling
responses (red background in top panel) and pathway optimization is critical to obtain a pathway topology that captures HepG2 function (limited red
background in bottom panel). Pathways are visualized using Cytoscape [54].
doi:10.1371/journal.pcbi.1000591.g002
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removes reactions that lead to false protein activations. An
example of the first case is the Insulin (INS)-induced AKT
activation that is maintained via the INSRIRbRIRS1tRPI3KR
PIP3RPDK1RAKT path (see INS to AKT path in Figure 2). An
example of a removed reaction is the TNFRRPI3K reaction
which is removed because there is no TNFa induced AKT
activation (see TNFRRPI3KR…RAKT in Figure 2). During the
optimization of the secondary objective (see Materials and
Methods), several reactions with no evidence of their existence
(no downstream measurements, or no stimuli) are removed. In this
step, the overall goodness of fit is not improved, but the size of the
topology is reduced. To illustrate this case, we add to the initial
topology the receptor IL6R but the associated stimulus IL6 is not
introduced on the experiments. After the secondary optimization,
all downstream reactions of IL6 are removed because no data are
present (see reaction arrows downstream for of IL6 in Figure 2).
Similarly, all reactions downstream of the bottom-of-the-network
key proteins are removed (e.g. CJUNRCFOS reaction in
Figure 2). All those reactions might be present in reality and
could have been kept if the secondary objective was not present.
Here, we apply the secondary objective and follow a network
trimming which removes all reactions that might be present in the
cell but due to the lack of measured signals or experimental
conditions cannot be verified. The resulting network is significantly
smaller but contains only elements for which there are solid
experimental evidence that explain the topology.
To validate our model, we also examine three scenarios where
we remove 20% of our experimental data, and then we try to
predict them. Specifically, we create three training datasets, each
time by removing all cases where one inhibitor is present (either
MEKi, PI3Ki, or p38i) and then we calculate how well our ILP-
optimized map can predict each of the inhibitor cases (see Figure
S2). For the MEKi, PI3Ki, and p38i scenarios the goodness of fit is
8.22%, 9.46%, 7.05% respectively and our ILP-formulation
converges on the same or slightly less optimal solutions compared
to the solutions obtained when the whole dataset is used for
training (4.47%, 7.76%, and 7.05% respectively) - See Figure S2.
Note that the errors given refer only to the subset considered in
each case, not the entire dataset. More extensive validations for
Boolean-type models on similar phospho-proteomic dataset can
also be found in Saez-Rodriguez et al. [18].
Comparison with genetic algorithm
In order to compare the ILP algorithm with the previously
published genetic algorithm (GA) we use the same initial topology
and the same normalized dataset [18]. The two algorithms
reached almost identical results (see Figure S3). For the ILP, the
computational requirements are manageable, in the order of a few
seconds (14.3 seconds for this example) on an Quad Core Intel
Xeon Processor E5405 (2.00GHz,2X6M L2,1333) running Linux
2.6.25.20 (using only one core). In comparison, the same
optimization problem using GA requires approximately 1 hour
on a similar power computer. The optimal pathway furnished by
the ILP matches all but 98 out of 880 experimental data, as
opposed to 110 mismatches in the topology furnished by the GA.
It has to be noted that GA does not provide termination criteria,
and it is conceivable that after even larger CPU times the GA
would have achieved the same fit as the ILP. In contrast the
deterministic solution of the ILP guarantees that an optimal fit (not
necessarily unique) has been identified within a user-specified
tolerance (10
23 in our case). In addition to the guaranteed optimal
solution, commercial ILP solvers are fast, robust and reliable. Note
that open-source ILP solvers also exist, but in our experience are
not yet adequate. Note also that for larger network topologies, the
differences in CPU time will become even more dramatic,
rendering the GA intractable.
The notable differences between the proposed method and the
method used in [18] is mainly due to fundamental algorithmic
differences: the technology behind deterministic ILP solvers
(branch-and-bound, branch-and-cut) is more sophisticated than
genetic algorithms, it employs the inherent linearity of the
problem, and makes use of the good scalability of linear programs
(sub-problems in branch-and-bound tree). In contrast, GA treats
the model as a black-box and does not exploit the problem
structure. Another point is that herein we used a well-established
commercial solver, whereas Saez-Rodriguez et al. [18] used their
own implementation of GA. Commercial deterministic ILP
solvers, such as CPLEX, rely on several decades of research and
development, and have extremely powerful features such as pre-
processors and node selection heuristics. Thus, they typically
become the default choice for ILPs.
Identifying drug effects via drug-induced topology
alterations
For the identification of the drug effects we make use of the
second dataset in HepG2s where drugs are applied together with
the same set of ligands. In this case, the ILP formulation is being
used with the HepG2 specific topology (topology obtained from
the previous step) and not the generic map. We also do not impose
inhibitor constrains the way we do for pathway optimization (e.g.,
PI3K inhibitor blocks the signal downstream of PI3K) but we let
the optimization algorithm decide which reaction(s) should be
removed in order to fit the drug-induced data.
The effect of Lapatinib (Figure 3a), the most selective and
specific EGFR inhibitor [32], is the complete removal of the
downstream reactions of the TGFa branch: TGFaRGRB2R
SOSRRASRPI3K and RASRRAF1RMEK1/2RERK1/2.
This resulted from the fact that Lapatinib blocks the TGFa
induced MEK1/2, ERK1/2, and AKT phosphosignals (Figure 3e).
Note that the PI3KR…RAKT branch is not removed because it
is being used by the HGF and INS path for the activation of AKT
that cannot be blocked by Lapatinib (Figure 3e).
Gefitinib, an EGFR tyrosine kinase inhibitor, alters the topology
in a very similar pattern as Lapatinib, but, interestingly enough, it
also results in the removal of the JNKRc-JUN branch (Figure 3b).
Closer examination of the raw data (Figure 3f) shows a potent
inhibition of IL1a- and (IL1a+TGFa)-induced cJUN activity upon
Gefitinib treatment. To follow up this interesting off-target effect,
we did a dose-response experiment where Gefitinib shows that it
can reduce the activation of cJUN signal induced by the IL1a
stimuli (Figure 3i). We believe that the inhibition of cJUN is not
due to the binding of Gefitinib in the upstream molecule JNK but
a collective effect of signaling inhibitions in several species that
take part in the path between IL1a and cJUN. For this reason, a
fitting with a typical dose response curve has been avoided and a
simple linear equation has been used instead (Figure 3i). Erlotinib,
another EGFR inhibitor, has the same effects as Gefitinib
(Figure 3c) but at the same time shows an effect in the
TRAF6RMAP3k7 reaction. This effects is probably because
IkB-a is inhibited in an IL1a -dependent but TNFa-independent
manner (see IkB-a signals upon IL1a and TNFa stimuli in Figure
S1); the only way for the ILP to satisfy this behavior is to remove
the transmission of signal before the merging of TNFa and IL1a
paths which can be done through the TRAF6RMAP3K reaction.
The ‘‘dirty’’ Raf inhibitor Sorafenib shows a very different
profile: it also blocks the JNKRc-JUN branch (Figure 3d) and in
addition affects the p38 path (see complete HSP27 inhibition upon
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PLoS Computational Biology | www.ploscompbiol.org 5 December 2009 | Volume 5 | Issue 12 | e1000591Figure 3. Drug-induced pathway alterations. (A–D) Red arrows denote drug effects, i.e., reactions that are removed from the HepG2 topology
by the ILP algorithm in order to fit the drug-altered phosphoprotein dataset. (E–H) Raw data that correspond to drug effects. Lines indicates the
signal between 0 minutes (untreated) and ‘‘early response’’ (average signal of 5 and 25 minutes post stimuli). (I) Off-target effect of Gefitinib. Dose
response curve shows that the EGFR inhibitor reduces cJUN activation upon IL1a treatment. R
2 corresponds to linear fit.
doi:10.1371/journal.pcbi.1000591.g003
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network optimization does not remove the RAFRERK1/2
reaction despite the fact that RAF is the main target of Sorafenib.
Close inspection of the data shows that Sorafenib reduces but does
not block the MEK1 phosphorylation (see MEK phosphorylation
in Figure 3h). This is in agreement with previous published results
where Sorafenib does not inhibit activation of the RAF/MEK/
ERK pathway in all human tumor cell lines [33] a finding that
highlights the importance of in-vivo assays for the quantification of
drug effects.
Discussion
In this article, we present an unbiased phosphoproteomic-based
approach and an optimization formulation to construct cell-type
specific pathways and to identify drug effects on those pathways.
For the pathway construction, we track 13 key phopshorylation
signals in 55 different conditions generated by the combinatorial
treatment of stimuli and inhibitors. Using Integer Linear
Programming (ILP) for pathway optimization we take a generic
network of 74 proteins and 105 reactions and construct a cell-type
specific network of 49 proteins and 44 reactions that spans
between the 5 stimuli and the 13 measured phosphorylated
proteins. In this network, we monitor 4 cases of drug-induced
pathway alterations using a similar computational scheme.
In comparison to all other protein-based target identification
approaches, our method is not based on measurements of drug
affinities either by in vitro or in vivo assays. Instead, we use an
‘‘operative’’ signaling network and rely on key phosphorylation
events and a-priori knowledge of possible connections to reveal the
topology and monitor its alterations under the presence of the
drug. Thus, our method is expandable to any type of intracellular
perturbations such as ATP-based and allosteric inhibitors, RNAi,
shRNA etc. Since no bait or MS is required, we have simple
ELISA-type experimental procedure with minimal requirements
of cell starting protein (,30,000 cells per condition), without
affinity immobilizations, protein fractionations, or carefully
optimized wash conditions. With our current semi-automated
procedures in our lab (robotic liquid handlers), we can achieve
total experimental and computational time for a similar size
experiment in less than a week. On the other side, our approach
can only detect signaling alterations in topologies bounded
between the applied stimuli and the measured phosphorylated
proteins and it misses off-target effects outside the constructed
network. The expansion of the constructed network depends
primarily on three factors: highly curated generic topology,
multiplex assay availability for ‘‘key’’ phosphorylation measure-
ments, and experimental cost. We believe that the explosive
growth of multiplexed phosphoproteomic assays, the rapid
reduction of the cost per datapoint, and the significant
improvement in quality of several pathways databases will
significantly increase the searching space for drug effects using
our proposed methodology. However, our search space will always
be significantly smaller compared to whole-genome based
approaches [8–11] because it requires (a) the input of a generic
pathway which is available only in well-studied pathways and (b)
good quality antibodies for the detection scheme. By merging our
phosphoproteomic method with genome-wide screening tech-
niques, we might be able to combine the strengths of both
approaches and increase the searching space for off-target drug
effects.
An important aspect of the current approach is the construction
of pathway maps. Pathway construction is a major endeavor in
biology and a variety of experimental [34–38] and computational
approaches that span from data-driven methodologies (e.g.,
statistical, unsupervised machine learning) to topology-based
methods (e.g., kinetic models based on ordinary differential
equations-ODEs) [17,35,38–41] have been developed. Our
approach, which is based on Boolean (logical) modeling
[26–28,42], represents a simplified topology-based method.
Compared to ODE-based methods, a logic model has limited
abilities to model kinetic behavior [25] (especially when modeling
feedback loops in single-step logic models) or even to model the
protein activity in a continuous fashion. On the flip side, logic
models do not require parameter estimation (sometimes ill-defined
from lack of experimental data) and thus can be applied for the
simulation of large topologies. A refinement of the model
formalism into multistep logic [28], fuzzy logic [43], or ODE-
based logic systems [44] may provide a more precise simulation of
the activity and time-dependency of the signaling network. Taking
into account the current limitations of experimental assays
(throughput, sensitivity, reliability, cost) we believe that Boolean
modeling is the method of choice with high predictive power when
large topologies are studied.
Optimizing pathway topologies is a relatively new approach for
the construction of cell-type specific pathways. Using Boolean
topology and Genetic Algorithm (GA) for an optimization scheme,
Saez-Rodriguez et al. [18] are able to fit a generic map to cell-type
specific map from phosphoprotein data. Here we present an
alternative method of optimal pathway identification based on
ILP. Compared to GA, our algorithm gives guaranteed globally
optimized map (the solution identified is guaranteed to be no
worse than 0.001 than any other possible solution). Additionally,
the computational cost has cut down dramatically and allows
pathway optimization with ,70 species to be performed on a
desktop computer in a matter of few seconds. Due to minimal
computational requirements ILP can be used for the construction
of large pathways (assuming that experimental capabilities can by
matched) and for the exploration of alternative reactions beyond
the generic topology to further improve the optimal fit. However,
several factors should be addressed before expanding our
formulation to larger topologies. Although our formulation is able
to identify a globally optimal solution, additional optimal solutions
might exist [18] in the same generic network and further more
solutions might arise when the optimization formulation is relaxed.
Larger and more interconnected networks increase the number of
solutions that are equally (or near equally) optimal. A possible way
to circumvent this problem is to reduce our network using
techniques that have been described previously in graph theory or
in [18]. Being aware of those limitations in the present manuscript
we described a ‘‘simple’’ and not highly interconnected network in
order to minimize redundancy of solutions. To address the issue of
finding a both unique and optimal solution we are currently
working on two complementary approaches: (a) instructing the
ILP solver to furnish a pool of near-optimal solutions and (b)
devising ‘‘clever stimulations’’ by taking into account experimental
limitations (i.e., combination of inhibitors, stimuli, and key protein
measurements) that maximally constrains the optimization scheme
and gives smaller number of unique solutions.
When applied in HepG2s, our approach identifies both known
and unanticipated results. As a positive control, it removes the
TGFa branch upon EGRF drug treatments. Another easily
understandable effect is Sorafenib’s inhibition of the pathway
downstream of p38 which can be explained by the drug’s target
affinity to p38a and p38b [32,45]. A surprising effect is the
removal of the JNKRcJUN reaction under the influence 3 out of
4 cancer drugs Erlotinib, Gefitinib and Sorafenib. Interestingly,
kinase profiles of those drugs [32] shows no medium or high
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Gefitinib shows a significant reduction of the cJUN activity upon
IL1a treatment. A possible explanation is that the signaling
propagation can collectively be attenuated from the low or
medium off-target inhibitions of several kinases upstream of JNK
and cJUN. This also might explain the inhibition curve in
Figure 3i, where Gefitinib inhibition of cJUN activation does not
follow a typical dose-response curve. In this context, sensitivity
analysis in ODE-based pathway models [46] have shown that
slight changes of reaction constants can have significant attenu-
ations on protein activities several steps downstream the network
and thus inhibitory curves cannot be simulated by simplified dose-
response models. Our findings also highlight a unique feature of
our approach: we find effects of drug’s promiscuity that cannot be
identified by the direct binding of the drug to the upstream target
but are the result of a collective effect of drug’s interactions with
several upstream molecules. Bait-based analysis cannot reveal
those effects since there is no binding involved between the drug
and the protein.
Understanding the interplay between cell function and drug action
is a major endeavor in the pharmaceutical industry. Here, we
provided a methodology to construct cell type specific maps and
identify drug effects on those maps. Our ILP formulation was able
to build the best possible topology from a set of a-priori determined
reactions and choose those, where their presence is confirmed
from high throughput phosphoprotein data. Since phosphoryla-
tion events are the ultimate reporters of protein/drug function the
use of high-throughput phosphoproteomic datasets gave an
advantage in data quality for modeling signaling network. We
believe our approach complements standard biochemical drug
profiling assays and sheds new light into the discovery of possible
mechanisms for drug’s efficacy and toxicity.
Materials and Methods
Experimental procedure: phosphoprotein dataset
HepG2 cells were purchased from ATCC (Manassas, VA), and
seeded on 96-well plates coated with collagen type I-coated (BD
Biosciences, Franklin Lakes, NJ) at 30,000 cells/well in DME
medium containing 10% Fetal Bovine Serum (FBS). The following
morning, cells were starved for 4 hours and treated with inhibitors
and/or drugs. Kinase inhibitors were used at concentrations
sufficient to inhibit at least 95% the phosphorylation of the nominal
target as determined by dose-response assays (presented in [17]).
AKT was chosen as the nominal target for Lapatinib, Erlotinib, and
Gefitinib. The following saturated concentrations were used: p38
(PHA818637, 20 nM), MEK (PD325901, 100 nM) and cMET
(JNJ38877605, 1mM), PI3K (PI-103, 10 mM), Lapatinib at 3uM
[47], Erlotinib at 1 uM [47], Gefitinib at 3uM [47], and Sorafenib
at 3 uM (based on its inhibitory activity on ERK1/2 phosphory-
lation [33]). Following incubation for 45 minutes with inhibitors
and/or drugs cells were treated with saturated levels of 5 ligands:
Tumor Necrosis Factor alpha (TNFa) at 100ng/ml, Interleukin 1
alpha (IL1a) at 10ng/ml, Insulin (INS) at 2uM, Transforming
Growth Factor (TGFa) at 100ng/ml, and Hepatocytes Growth
Factor (HGF) at 100 ng/ml. Each ligand was added alone or in
pairsandcelllysateswerecollectedat0,5,and 25 minutesfollowing
the cytokine stimulation. The 5 and 25 minutes lysates were mixed
together in 1:1 ratio and the mixed lysate was measured as an
indicator of the ‘‘average early signaling response’’. The 5 and
25 minute time points were identified in a preliminary experiment
as the optimal time points that maximally captured early
phosphorylation activities [17].
A major improvement in the present dataset as compared to [17]
was the ‘‘in-vitro’’ averaging of the signals from 5 and 25 minutes
rather than ‘‘in-silico’’ averaging (i.e., first both time points are
measured,thenwe take the average). Three arethe mainadvantages
using such approach: 1) two signals are used instead of one and thus
very early signalling responses can be captured, 2) the experimental
cost is reduced by 50% (or more for averaging multiple time points),
and 3) we achieved the averaging of some signals that could not be
measured independently because their ‘‘active’’ state is reaching the
saturation limits of our measuring instrument.
From each lysate we measured 13 phosphorylation activities that
we considered ‘‘key phosphorylation events’’ using a Luminex 200
system (Luminex Corp, Austin, TX). The 13-plex phospho-protein
bead setfrom Bio-Radwasused to assay p70S6K (Thr421/Ser424),
CREB (Ser133), p38 (Thr180/Tyr182), MEK1 (Ser217/Ser221),
JNK (Thr183/Tyr185), HSP27 (Ser78), ERK1/2 (Thr202/
Tyr204, Thr185/Tyr187), c-JUN (Ser63), IRS-1 (Ser636/
Ser639), IkB-a (Ser32/Ser36), Histone H3 (Ser10), Akt (Ser473),
and IR-b (Tyr1146). Data were normalized and plotted using with
DataRail [48]. For the construction of the dose response curve in
Figure 3i, HepG2 were starved for 4 hours and then incubated with
Gefitinib (from 20uM down to 27nM – 3 fold dilution) for
45 minutes followed by incubation with IL1a at 10ng/ml final
concentration for 30 minutes. Duplicatelysates wereanalyzed using
the c-JUN (Ser63) beads in the Luminex 200 system.
Computational procedure: ILP formulation
Here, we describe how the Boolean model described in [18] can
be reformulated as an ILP. Note that such a transformation was
recently performed for a different problem, namely the satisfia-
bility, by [49]. A pathway is defined as a set of reactions
i~1,...,nr and species j~1,...,ns. Each reaction has three
corresponding index sets, namely the index set of signaling
molecules Ri, inhibitors Ii, and ‘‘products’’ Pi (‘‘product’’ can also
correspond to the phosphorylation level of the protein). These sets
are all subsets of the species index set (Ri,Ii,Pi5f1,...,nsg).
Typically, these subsets have very small cardinality (few species),
e.g., jRij~0,1,2; jIij~0,1; jPij~1,2; jRijzjIij~1,2. A reaction
takes place if and only if all reagents and no inhibitors are present.
If a reaction takes place, all products are formed. Note that
reactions without products as well as reactions with neither
reagents nor inhibitors will be excluded here.
While typically the set of species is known, the set of reactions is
not known. Rather, only a superset of potential reactions is
postulated. The goal of the proposed formulation is to find an
optimal (in some sense) set of reactions out of such a superset. To
that extent binary variables yi are introduced, indicating if a
reaction is possible or not (yi~0 connection not present, yi~1
connection present).
A set of experiments is performed, indexed by the superscript
k~1,...,ne. In each experiment a subset of species is introduced
to the system and another subset is excluded from the system.
These are summarized by the index sets Mk,1 and Mk,0
respectively (two for each experiment). In the proposed formula-
tion, constants are introduced for all such species, respectively
xk
j ~1 and xk
j ~0. In the following it will be assumed that these
species do not appear as products in any reaction; this assumption
is not limiting, since in the experiments performed only
extracellular species and inhibitors are manipulated. In the
experiments a third subset of the species is measured (index set
Mk,2) and for the remaining species no information is available. In
the proposed formulation for each of the experiments and each
such species a binary decision variable xk
j [ f0,1g is introduced
indicating if the species j is present (xk
j ~1) or not (xk
j ~0) in the
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in the absence of loops, xk
j [ ½0,1  can be used for species that are
not input species (see Text S1). This has some computational
advantages.
The last group of variables zk
i introduced indicate if reaction i
will take place (zk
i ~1) or not (zk
i ~0) in the experiment k
according to the model predictions. It is proved that a real variable
zk
i [ ½0,1  can be used equivalently (see Text S1). This reformu-
lation has some computational advantages.
For the case that a species is measured, the measurement is
defined as x
k,m
j . For Boolean measurements x
k,m
j [ f0,1g; otherwise
x
k,m
j [ ½0,1  (assuming a scaling as afforementioned). The primary
objective function is formed aiming to minimize the weighted error
between model predictions and measurements
P
j,k ak
j jxk
j {x
k,m
j j.
The absolute value is reformulated as x
k,m
j z(1{2x
k,m
j )xk
j . It can
be easily verified that for binary xk
j and for x
k,m
j [ f0,1g this
reformulation is valid:
1. xk
j ~0:
x
k,m
j z(1{2x
k,m
j )xk
j ~x
k,m
j z(1{2x
k,m
j )0~x
k,m
j ~jx
k,m
j j~jx
k,m
j {xk
j j:
2. xk
j ~1:
x
k,m
j z(1{2x
k,m
j )xk
j ~x
k,m
j z(1{2x
k,m
j )1~1{x
k,m
j ~j1{x
k,m
j j~jxk
j {x
k,m
j j:
Note also that alternative norms, such as least-squares errors,
could be also used. The resulting optimization problem would still
be an ILP, since the objective function involves only integer
variables. For instance for the least-square error objective function
the following linear reformulation is valid:
(xk
j {x
k,m
j )
2~(xk
j )
2{(2xk
j x
k,m
j )z(x
k,m
j )
2~(xk
j ){(2xk
j x
k,m
j )z(x
k,m
j )
2
The secondary objective is to minimize the weighted number of
possible reactions
P
i biyi. In multiobjective optimization typically
the concept of Pareto-optimal or noninferior solution is introduced, i.e.,
a set of decision variable values, such that if one tries to improve
one objective, another will be degraded [50]. The set of Pareto
points forms the Pareto-optimal curve. Here, however, the
primary objective is considered much more important than the
secondary objective. Therefore, a single Pareto-optimal point is
obtained, by first minimizing the primary objective and then the
secondary objective by requiring that the former (more important)
objectives are not worsened, see also [51–53].
The ILP proposed can be summarized as:
min
X,y,Z
X ne
k~1
X
j[Mk,2
ak
j x
k,m
j z(1{2x
k,m
j )xk
j
  
;
X nr
i~1
biyi ð1Þ
s:t:
X nr
i~1
al
iyiƒbl, l~1,...,nc, ð2Þ
zk
i ƒyi, i~1,...,nr, k~1,...,ne: ð3Þ
zk
i ƒxk
j , i~1,...,nr, k~1,...,ne, j [ Ri ð4Þ
zk
i ƒ1{xk
j , i~1,...,nr, k~1,...,ne, j [ Ii: ð5Þ
zk
i §yiz
X
j[Ri
xk
j {1
  
{
X
j[Ii
xk
j
  
, i~1,...,nr, k~1,...,ne: ð6Þ
xk
j §zk
i , i~1,...,nr, k~1,...,ne, j [ Pi: ð7Þ
xk
j ƒ
X
i~1,...,nr:j[Pi
zk
i , j~1,...,ns, k~1,...,ne: ð8Þ
xk
j ~0, k~1,...,ne, j [ Mk,0 ð9Þ
xk
j ~1, k~1,...,ne, j [ Mk,1 ð10Þ
X [ f0,1g
ne|ns, y [ f0,1g
nr, Z [ f0,1g
ne|nr, ð11Þ
where the objectives are separated by a semi-colon. Note that for
the elements of the matrices X and Z, the row index (experiment)
is indicated as superscript, and the column index (species and
reactions respectively) is indicated as subscript.
In formulation (1)–(11) for the manipulated species binary
decision variables along with the constraints (9) and (10) are
introduced. This simplifies notation. In the implementation, these
variables are replaced by constants. Alternatively the preprocessor
of the optimization solver can be used to exclude these trivial
variables.
In the following the reasoning for the formulation is given. The
first set of constraints, i.e., (2) allow the modeler to limit the
combinations of connectivities considered. For instance, suppose
that two reagents R1, R2 form a product P, but it is not known if
both reagents (AND) or either (OR) are required. This can be
modeled as three potential reactions
r1 : R1zR2?P
r2 : R1?P
r3 : R2?P,
with the additional constraint that r1 excludes r2 and r3, which
can be modeled as two linear inequalities:
yr1zyr2ƒ1
yr1zyr3ƒ1:
The constraints (3) indicate that a reaction can only take place if it
(6)
Phosphoproteomic Identification of Drug Effects
PLoS Computational Biology | www.ploscompbiol.org 9 December 2009 | Volume 5 | Issue 12 | e1000591is possible (yi~1). This can be seen easily, since yi~0, gives zk
i ƒ0
and together with zk
i [ f0,1g we obtain zk
i ~0. Similarly, the
constraints (4) and (5) ensure respectively that a reaction can only
take place if all reagents and no inhibitors are present. If for
instance a reagent is absent, zk
i ~0 is enforced, and the other
constraints are redundant. On the other hand, the constraints (6)
enforce that if a reaction is possible, all reagents are present, and
no inhibitors are present, then the reaction will take place (zk
i ~1).
The constraints (7) ensure that a species will be formed if some
reaction in which it is a product occurs. Note that multiple
reactions can give the same species; mathematically this will result
in redundant constraints. In contrast, the constraints (8) enforce
that a species will not be present if all reactions in which it appears
as a product do not occur. Recall that manipulated species are not
considered as products in reactions. Note also, that it would be
possible to combine the constraints (7) into a single constraint for
each species, e.g.,
xk
j §
X
i~1,...,nr:j[Pi
zk
i =
X
i~1,...,nr:j[Pi
1, j~1,...,ns, k~1,...,ne,
but this would result in weaker LP-relaxations. Also the
reformulation of xk
j to ½0,1  would no longer be exact.
In the present study, our ILP formulation was utilized in two
different circumstances. For the creation of the cell-type specific
pathway using combinations of inhibitors and stimuli our ILP
formulation included 27887 constraints and 9732 variables. For
each drug case, where the reduced and optimized pathway was
utilized, we had 2477 constraints and 947 variables.
Computational procedure: goodness of fit
For the goodness of fit, we calculated the percentage error as:
Error~
X ns
j~1
x
k,m
j {xk
j
     
     
,
ns,m:100%
Note that for binary xk
j and x
k,m
j [ ½0,1  the percentage error
cannot be 0% even when there is no mismatch between model and
experiment data. Another way to quantify the goodness of fit is by
counting the number of mismatches: the cases where the rounded
experimental value (0 or 1) is not the same with the computational
value, or in other words, when experimental – computational
error is more than 0.5.
Supporting Information
Figure S1 Raw data for the construction of the cell-type specific
map and the evaluation of the drug effects. The signals in the
Y-axis correspond to the measurements of the phosphorylated
residues listed in Materials and Methods. Each column corre-
sponds to cytokine or cytokine mix and each sub-column to the
presence of an inhibitor or drug. The numbers to the left are the
maximum values across all treatments measured as arbitrary
fluorescent intensities.
Found at: doi:10.1371/journal.pcbi.1000591.s001 (0.52 MB PDF)
Figure S2 Model Validation. The first panel shows the
optimization results when the full dataset (shown in Figure 2)
has been used as training dataset. To validate our model, we
created three subsets, in which 20% of our experimental cases are
removed that correspond to the treatments with PI3K inhibitor
(2nd panel), MEK inhibitor (3rd panel), and p38 inhibitor (bottom
panel), and we trained our model against them. The data left out is
then used as test dataset for prediction (see highlighted strips in
each panel). The error of prediction of the test subsets
(error=goodness of fit as describes in Materials and Methods) is
shown on the right of each panel.
Found at: doi:10.1371/journal.pcbi.1000591.s002 (0.91 MB PDF)
Figure S3 Comparison between genetic algorithm and ILP.
Both algorithms performed well and achieved very similar
solutions. Red background denotes inconsistency between pre-
dicted values and experimental data: ILP matched all but 98 out of
880 experimental data, as opposed to 110 mismatches in the
topology furnished by the GA. The computational time for ILP
was 14.3 sec as opposed to 1approximately one hour for GA.
Found at: doi:10.1371/journal.pcbi.1000591.s003 (0.63 MB PDF)
Text S1 Equivalent reformulation as MILP
Found at: doi:10.1371/journal.pcbi.1000591.s004 (0.03 MB PDF)
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